Benefits
Type 2 diabetes — modest improvements in glucose markers
In type 2 diabetes patients, concentrated broccoli sprout extract over 8-12 weeks modestly reduces fasting glucose, HbA1c, insulin resistance, and oxidized LDL. Effects are most pronounced in patients with poorly-controlled disease at baseline. Magnitude is smaller than oral antidiabetics but reproducible across multiple trials. Reasonable adjunct alongside metformin and lifestyle measures; not a substitute for first-line diabetes therapy.
Autism spectrum disorder — striking initial signal, weaker replication
An early high-profile trial in young men with moderate-to-severe autism showed substantial improvements in behavior and social responsiveness scores over 18 weeks of sulforaphane, with effects reversing on washout. A subsequent replication in children failed to reproduce the primary outcome. Honest framing: striking original signal, less compelling replication. Reasonable low-risk adjunct given excellent safety; expectations should be calibrated — not an established autism intervention.
H. pylori — suppression, not eradication
Daily broccoli sprout consumption (about 70 g/day for 8 weeks) reduces H. pylori colonization markers and gastric inflammation in infected adults. Critical caveat: this is suppression, not eradication — markers come back after discontinuing. Reasonable dietary adjunct for H. pylori carriers, particularly those with intolerance to triple-therapy antibiotics. Not a substitute for proper eradication therapy when treatment is medically indicated.
Cancer prevention — strong mechanism, limited human outcome data
Sulforaphane has extensive preclinical evidence for cancer chemoprevention through multiple pathways. Human trials show enhanced excretion of airborne carcinogens in high-pollution populations and modest changes in prostate cancer biomarkers. But no large-scale trials demonstrate actual cancer prevention or treatment outcomes in humans. Reasonable as part of a cruciferous-vegetable-rich diet for general health; don't expect cancer prevention from supplementation specifically.
Cardiovascular markers — preliminary
Smaller human trials show modest reductions in CRP and oxidized LDL plus improved endothelial function. Mechanistically coherent (sulforaphane activates protective antioxidant pathways) but the clinical evidence base is small and short-duration. Plausible cardiovascular-supportive role; not yet validated as a cardiovascular intervention. Most relevant in metabolic syndrome contexts where multiple cardiometabolic markers benefit simultaneously rather than as standalone CV strategy.
Product form matters absolutely — myrosinase is essential
Glucoraphanin alone is biologically inactive — it has to be converted to sulforaphane (the actual bioactive) by an enzyme called myrosinase. Plasma sulforaphane levels differ 3-7× between glucoraphanin-only products and those with active myrosinase included. Practical guidance: choose either pre-formed sulforaphane OR glucoraphanin combined with active myrosinase (Avmacol®, Truebroc® with myrosinase). Generic 'broccoli extract' without myrosinase status disclosed is unreliable.
Antioxidant pathway activation — what's actually happening
Sulforaphane is one of the most potent dietary activators of the body's master antioxidant defense system. Practical implication: rather than acting as a direct antioxidant itself (like vitamin C does), sulforaphane signals your cells to upregulate their own protective machinery — a fundamentally different and more durable approach. This activation underlies the broader clinical research across diabetes, cardiovascular, and cancer indications.
Mechanism of action
Glucoraphanin to sulforaphane conversion
In intact broccoli plants, glucoraphanin and the enzyme myrosinase are stored in separate cellular compartments. When tissue is damaged (chewing, chopping, fresh sprout consumption), they combine and myrosinase hydrolyzes glucoraphanin to release sulforaphane. Cooking destroys myrosinase — boiled broccoli has minimal sulforaphane production unless gut bacteria provide microbial myrosinase. The 'eat them raw' or 'lightly steam' culinary advice for broccoli traces directly to this enzymatic chemistry.
NRF2/KEAP1 pathway activation
Sulforaphane modifies specific cysteine residues on KEAP1 (the cytoplasmic suppressor of NRF2), disrupting the KEAP1-NRF2 interaction. Released NRF2 translocates to the nucleus, binds the antioxidant response element (are) on phase II detoxification gene promoters, and drives expression of dozens of cytoprotective enzymes. This is the central mechanism for both the antioxidant claims and the cancer chemoprevention rationale. The pathway is conserved across animal models and human cell lines.
Phase II enzyme induction
Downstream NRF2 targets include glutathione S-transferases (GSTs), NAD(P)H quinone oxidoreductase 1 (NQO1), heme oxygenase-1 (HO-1), glutamate-cysteine ligase (GCL, rate-limiting glutathione synthesis enzyme), and multiple drug-metabolizing transporters. Collectively these enzymes detoxify electrophiles, quench reactive oxygen species, and conjugate xenobiotics for excretion. This is the molecular basis for the 'detoxification support' positioning that has emerged in the consumer wellness space.
Histone deacetylase (HDAC) inhibition
Sulforaphane and its metabolites also inhibit class I and II histone deacetylases at micromolar concentrations. HDAC inhibition is one of the proposed mechanisms for the cancer chemoprevention effects observed in preclinical models (epigenetic regulation of tumor suppressor expression). Effect size in vivo at dietary doses is debated.
Why broccoli sprouts >> mature broccoli
Broccoli sprouts (3-day-old germinated seeds) contain 20-100× more glucoraphanin than mature broccoli on a fresh-weight basis. Talalay's group demonstrated this concentration difference in 1997 and developed standardized sprout production techniques as a basis for reproducible chemoprevention research. Mature broccoli is still a worthwhile dietary source but cannot match sprout-based supplementation for therapeutic dose ranges.
Clinical trials
Landmark double-blind placebo-controlled clinical trial at MGH Lurie Center for Autism. 44 young men aged 13-27 with moderate-to-severe ASD randomized to broccoli sprout extract (50-150 μmol/day sulforaphane based on body weight) or placebo for 18 weeks, followed by 4 weeks no-treatment.
44 young men aged 13-27 with moderate-to-severe ASD
Landmark double-blind placebo-controlled clinical trial at MGH Lurie Center for Autism. 44 young men aged 13-27 with moderate-to-severe ASD randomized to broccoli sprout extract (50-150 μmol/day sulforaphane based on body weight) or placebo for 18 weeks, followed by 4 weeks no-treatment. Aberrant Behavior Checklist (ABC) and Social Responsiveness Scale (SRS) significantly improved in sulforaphane group. Effects reversed after washout. Clinicaltrials.gov NCT01474993, FDA IND 113542. Used freeze-dried broccoli sprout extract from Cullman Chemoprotection Center at Johns Hopkins.
Clinical trial in 45 children with ASD randomized to sulforaphane vs. placebo for 15 weeks.
45 children with ASD
Clinical trial in 45 children with ASD randomized to sulforaphane vs. placebo for 15 weeks. Treatment effects on the primary outcome (Ohio Autism Clinical Impressions Scale) were not significant between groups at 7 and 15 weeks. Some metabolomic changes detected. Important counterweight to the 2014 PNAS finding — the original effect may be specific to older adolescents/adults with severe ASD rather than generalizable across age and severity. Politte Avmacol® replication (NCT02909959) results pending.
Clinical trial in 81 patients with type 2 diabetes randomized to 10 g/day broccoli sprout powder (BSP), 5 g/day BSP, or placebo for 4 weeks.
81 patients with type 2 diabetes
Clinical trial in 81 patients with type 2 diabetes randomized to 10 g/day broccoli sprout powder (BSP), 5 g/day BSP, or placebo for 4 weeks. High-dose group showed reduced insulin resistance (HOMA-IR), serum insulin, and oxidized LDL. Establishes a clinical signal in T2D consistent with NRF2-mediated reduction of oxidative stress and improvement in insulin sensitivity. Subsequent (Sci Transl Med 9:eaah4477) extended this in 97 obese T2D patients on concentrated extract for 12 weeks, with reduced fasting glucose and HbA1c.
Clinical trial in 48 H. pylori-infected adults in Japan randomized to 70 g/day broccoli sprouts (rich in glucoraphanin) or alfalfa sprouts placebo for 8 weeks.
Clinical population described in trial publication.
Clinical trial in 48 H. pylori-infected adults in Japan randomized to 70 g/day broccoli sprouts (rich in glucoraphanin) or alfalfa sprouts placebo for 8 weeks. Sprout group showed reduced urea breath test values and stool H. pylori antigen. Effects regressed after sprout discontinuation. Suggests suppression rather than eradication; complementary to but not replacement for clinical eradication therapy.